Poseida Therapeutics (PSTX) Provides Business Update
Poseida Therapeutics (PSTX) issued a business update covering recent developments.
anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering, and the other risks described in Poseida’s filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. ### Investor contact: Alex Lobo Stern Investor Relations Alex.lobo@sternir.com Media contact: Sarah Thailing Senior Director, Corporate Communications and IR Poseida Therapeutics, Inc. 858-605-3717
🔍 Detailed Event Analysis:
AI Summary: Poseida Therapeutics has commenced an underwritten public offering of shares of its common stock. Poseida expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares. The offering is subject to market and other conditions, and there can be no assurance whether or when the offering may be completed.
Key Elements Identified:
Drugs/Compounds: managers, offered, sold
Organizations: Poseida, Poseida Therapeutics Announces Proposed Public Offering of, LLC
📋 Poseida Therapeutics, Inc. (PSTX) - Other Event
Filing Date: 2022-08-04
Accepted: 2022-08-04 16:57:13
Event Type: Other Event
Event Details:
🔍 Detailed Event Analysis:
AI Summary: Poseida Therapeutics has commenced an underwritten public offering of shares of its common stock. Poseida expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares. The offering is subject to market and other conditions, and there can be no assurance whether or when the offering may be completed.
Key Elements Identified:
💼 Business Developments:
No business developments data available.
Structured Data: